Table 1 Baseline characteristics of included patients
Characteristics | N(%) |
|---|---|
Gender(n) | |
Male | 22 (44.9%) |
Female | 27 (55.1%) |
Age (median, range) (y) | 62 (26–80) |
Smoking history (n) | |
Never | 40 (81.6%) |
Former or current | 9 (19.4%) |
Location of the primary site (n) | |
Upper lobe | 28 (56.6%) |
Middle and lower lob | 21 (43.4%) |
TNM stage(n) | |
IIIA-IIIC | 8 (16.3%) |
IVA | 25 (51.0%) |
IVB | 16 (32.7%) |
Type of EGFR mutation(n) | |
EGFR exon 19 | 23 (46.9%) |
EGFR exon 21 | 26 (53.1%) |
No. of lines of aumolertinib therapy(n) | |
1 | 26 (53.1%) |
2 | 23 (46.9%) |
Time of TKI before TRT (median, range) (d) | 68 (0–743) |
Total dose(median, range) (Gy) | 55 (30–75) |
Dose per fraction (median, range) (Gy) | 2.2 (1.5–4) |
GTV size (median, range) (ml) | 24.8 (1.3–236.28) |
PTV size (median, range) (ml) | 116 (7.5–603.2) |
MLD (median, range) (Gy) | 6.36 (0.77–13.77) |
Progression before TRT (n) | |
No | 33 (67.3%) |
Yes | 16 (32.7%) |
Overlap time of TKI and TRT (median, range) (d) | 32 (12–46) |